PPIDT00352
Drug Information
| Name | Pegvaliase |
|---|---|
| Sequence | MKTLSQAQSKTSSQQFSFTGNSSANVIIGNQKLTINDVARVARNGTLVSLTNNTDILQGIQASCDYINNAVESGEPIYGVTSGFGGMANVAISREQASELQTNLVWFLKTGAGNKLPLADVRAAMLLRANSHMRGASGIRLELIKRMEIFLNAGVTPYVYEFGSIGASGDLVPLSYITGSLIGLDPSFKVDFNGKEMDAPTALRQLNLSPLTLLPKEGLAMMNGTSVMTGIAANCVYDTQILTAIAMGVHALDIQALNGTNQSFHPFIHNSKPHPGQLWAADQMISLLANSQLVRDELDGKHDYRDHELIQDRYSLRCLPQYLGPIVDGISQIAKQIEIEINSVTDNPLIDVDNQASYHGGNFLGQYVGMGMDHLRYYIGLLAKHLDVQIALLASPEFSNGLPPSLLGNRERKVNMGLKGLQICGNSIMPLLTFYGNSIADRFPTHAEQFNQNINSQGYTSATLARRSVDIFQNYVAIALMFGVQAVDLRTYKKTGHYDARASLSPATERLYSAVRHVVGQKPTSDRPYIWNDNEQGLDEHIARISADIAAGGVIVQAVQDILPSLH |
| DrugBank_ID | DB12839 |
| Type | biotech |
| Indication | Pegvaliase is indicated for the management of phenylketonuria (PKU) in adult patients who have uncontrolled blood phenylalanine concentrations greater than 600 micromol/L on existing management.[L42725] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, solution | Parenteral; Subcutaneous |
10 MG
|
| Injection, solution | Parenteral; Subcutaneous |
2.5 MG
|
| Injection, solution | Parenteral; Subcutaneous |
20 MG
|
| Injection, solution | Subcutaneous |
10 mg/0.5mL
|
| Injection, solution | Subcutaneous |
10 mg
|
| Injection, solution | Subcutaneous |
2.5 mg/0.5mL
|
| Injection, solution | Subcutaneous |
2.5 mg
|
| Injection, solution | Subcutaneous |
20 mg/1mL
|
| Injection, solution | Subcutaneous |
20 mg
|
| Solution | Subcutaneous |
10 mg / 0.5 mL
|
| Solution | Subcutaneous |
2.5 mg / 0.5 mL
|
| Solution | Subcutaneous |
20 mg / mL
|